26 September 2019 - Some women diagnosed with ovarian cancer could have their survival rates significantly increased after the Therapeutic Goods Administration approved a drug treatment for newly diagnosed sufferers.

The drug olaparib is available to women who have experienced recurrent ovarian cancer, but the TGA has now approved its use for those newly diagnosed with advanced high-grade ovarian cancer who carry the BRCA1 or BRCA2 gene mutation.

About 15 per cent of women ­diagnosed with high-grade ovarian cancer harbour the BRCA1 or BRCA2 gene mutation, which is also linked to breast cancer.

Read The Australian article